Home » Stocks » ANPC

AnPac Bio-Medical Science Co. Ltd. (ANPC)

Stock Price: $5.92 USD -0.08 (-1.33%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $5.91 -0.01 (-0.17%) Jan 22, 6:06 PM
Market Cap 66.31M
Revenue (ttm) 1.55M
Net Income (ttm) -14.44M
Shares Out 11.20M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $5.92
Previous Close $6.00
Change ($) -0.08
Change (%) -1.33%
Day's Open 5.93
Day's Range 5.91 - 6.05
Day's Volume 23,701
52-Week Range 3.21 - 11.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
24/7 Wall Street - 1 month ago

Initial public offerings (IPOs) have been a hot topic of late, with big names like Airbnb and DoorDash having some of the biggest showings this year.

Other stocks mentioned: CSPR, DNK, GRIL, LIZI, PROG, VEL
Benzinga - 1 month ago

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-sp...

Other stocks mentioned: ARPO, ARVN, SYBX, VERU
GlobeNewsWire - 1 month ago

SAN JOSE, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the Un...

GlobeNewsWire - 1 month ago

SAN JOSE, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United Sta...

Benzinga - 1 month ago

AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC) shares were advancing strongly Wednesday after the company reported strong third-quarter testing volume and issued a strong full-year outl...

Benzinga - 1 month ago

AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with ca...

Other stocks mentioned: AIM, RNLX
InvestorPlace - 1 month ago

AnPac Bio (ANPC) news for Wednesday concerning performance during the company's third quarter of 2020 have ANPC stock on the rise. The post AnPac Bio News: Why ANPC Stock Is Skyrocketing 110% ...

GlobeNewsWire - 1 month ago

SAN JOSE, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China an...

GlobeNewsWire - 2 months ago

SAN JOSE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China an...

GlobeNewsWire - 2 months ago

SAN JOSE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China an...

GlobeNewsWire - 2 months ago

SAN JOSE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China an...

GlobeNewsWire - 2 months ago

SAN JOSE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the Un...

GlobeNewsWire - 3 months ago

SAN JOSE, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China an...

GlobeNewsWire - 3 months ago

SAN JOSE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China an...

Seeking Alpha - 4 months ago

AnPac Bio-Medical Science Co., Ltd (ANPC) CEO Chris Yu on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

SAN JOSE, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China...

Zacks Investment Research - 4 months ago

Companies in the news are: IMAB, LMPX, DPW, ANPC

Other stocks mentioned: DPW, IMAB
InvestorPlace - 4 months ago

AnPac Bio-Medical Science (ANPC) saw an increase to ANPC stock on Friday following positive results from a clinical trial. The post Why AnPac Bio-Medical Science Stock Is Soaring 7% Today appe...

GlobeNewsWire - 4 months ago

SAN JOSE, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China...

GlobeNewsWire - 4 months ago

Earnings Call Scheduled for 8:00 am ET on September 10, 2020 Earnings Call Scheduled for 8:00 am ET on September 10, 2020

GlobeNewsWire - 4 months ago

SAN JOSE, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

GlobeNewsWire - 5 months ago

SAN JOSE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

24/7 Wall Street - 5 months ago

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) shares surged higher on Friday after the company reaffirmed its status as a COVID-19 stock.

GlobeNewsWire - 5 months ago

SAN JOSE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

GlobeNewsWire - 5 months ago

SAN JOSE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

GlobeNewsWire - 5 months ago

SAN JOSE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

GlobeNewsWire - 6 months ago

SAN JOSE, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

GlobeNewsWire - 6 months ago

SAN JOSE, Calif., June 26, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

GlobeNewsWire - 7 months ago

SAN JOSE, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China ...

24/7 Wall Street - 7 months ago

The announcement that AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) has entered into a three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management...

About ANPC

Anpac Bio-Medical Science Company, a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.

Industry
Biotechnology
IPO Date
Jan 30, 2020
CEO
Dr. Chris Chang Yu
Employees
111
Stock Exchange
NASDAQ
Ticker Symbol
ANPC
Full Company Profile

Financial Performance

In 2019, ANPC's revenue was 10.85 million, an increase of 5.80% compared to the previous year's 10.25 million. Losses were -101.06 million, 140.3% more than in 2018.

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for ANPC stock is "Strong Buy" and the 12-month stock price forecast is 13.00.

Price Target
$13.00
Analyst Consensus: Strong Buy